Study on MK-6070 for Advanced Cancers with DLL3 Expression

Inclusion Criteria

• Have a confirmed diagnosis of cancer that expresses the DLL3 protein.
• Have small cell lung cancer (SCLC) that has returned or not responded to at least one previous treatment, including platinum-based chemotherapy.
• Have Neuroendocrine Prostate Cancer (NEPC) that has returned or not responded to standard treatments.
• Have other high-grade neuroendocrine tumors that:
  • Have returned or not responded to standard treatments.
  • Do not have a standard treatment available.
  • Are not suitable for standard treatment as decided by the doctor.
• Must be able to provide a previous or new tissue sample for testing.

Exclusion Criteria

• Have untreated cancer that has spread to the brain or spinal cord.
• Have a type of brain cancer or other primary brain tumors.
• Have spinal cord compression or uncontrolled disease around the spine.
• Have a history of bleeding in the brain or spinal cord.
• Have active neurological conditions related to cancer.
• Have uncontrolled fluid buildup around the lungs, heart, or abdomen that needs frequent drainage.
• Have a history of autoimmune diseases or immune deficiencies, such as lupus or rheumatoid arthritis.
• Are currently taking medications that suppress the immune system, like high-dose steroids, within two weeks before starting the study.
• Have had significant heart disease or stroke within the last six months.
• Have active hepatitis A, B, or C infections, unless well-controlled.
• Have uncontrolled HIV infection, unless well-controlled.
• Have had a stem cell or organ transplant.
• Have taken immune-boosting drugs like interferon within four weeks before starting the study.
• Have had severe allergic reactions to certain types of antibodies.
• Have a history of lung diseases like pulmonary fibrosis or pneumonitis, unless related to past radiation treatment.
• Have taken another investigational drug within three weeks before starting the study.